Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 11;290(3):763–779. doi: 10.1111/febs.16614

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Fig. 1 — Identification of abnormally activated G6PD in breast cancer. (A) Gene expression of G6PD in normal people (n = 291) and breast cancer patients (n = 1085) was analysed by the StarBase 3.0 website. (B) The relationship between G6PD expression and the survival rate in human samples [n (high) = 400, n (low) = 400] was analysed by the StarBase 3.0 website. (C) Immunoblot analyses of and G6PD in MCF‐7 cells compared to MCF‐10A cells. (D) q‐PCR analysis of the transcription levels of G6PD in MDA‐231 and MCF‐7 cells compared to MCF‐10A cells. (E) Immunoblot analyses of G6PD, PR, and ERα protein in breast cancer patients compared to normal people (N: Normal, C: Cancer). (F) Transcription levels of G6PD were measured using q‐PCR on mRNA prepared from breast cancer patients and normal breast samples. (G) IHC staining detected G6PD in breast cancer tissue and paracarcinoma tissue in humans. 200× magnification. **P < 0.01, ****P < 0.001.